A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer

PURPOSE: A Phase 2 trial of stereotactic radiotherapy and in situ cytotoxic virus therapy in patients with metastatic triple-negative breast cancer (mTNBC) followed by pembrolizumab (STOMP) was designed to evaluate dual approach of enhancing single-agent immune checkpoint blockade with adenovirus-me...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kai, Xu, Yitian, Zhang, Licheng, Niravath, Polly, Darcourt, Jorge, Patel, Tejal, Teh, Bin S., Farach, Andrew M., Guerrero, Carlo, Mathur, Sunil, Sultenfuss, Mark A., Gupta, Nakul, Schwartz, Mary R., Haley, Susan L., Nair, Sindhu, Li, Xiaoxian, Nguyen, Thi Truc Anh, Butner, Joseph D., Ensor, Joe, Mejia, Jaime A., Mei, Zhuyong, Butler, E. Brian, Chen, Shu-hsia, Bernicker, Eric H., Chang, Jenny C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561553/
https://www.ncbi.nlm.nih.gov/pubmed/35877117
http://dx.doi.org/10.1158/1078-0432.CCR-22-0622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561553/
https://www.ncbi.nlm.nih.gov/pubmed/35877117
http://dx.doi.org/10.1158/1078-0432.CCR-22-0622

Ejemplares similares